JP2016512198A5 - - Google Patents

Download PDF

Info

Publication number
JP2016512198A5
JP2016512198A5 JP2015561594A JP2015561594A JP2016512198A5 JP 2016512198 A5 JP2016512198 A5 JP 2016512198A5 JP 2015561594 A JP2015561594 A JP 2015561594A JP 2015561594 A JP2015561594 A JP 2015561594A JP 2016512198 A5 JP2016512198 A5 JP 2016512198A5
Authority
JP
Japan
Prior art keywords
independently selected
group
optionally substituted
hydrogen
aliphatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015561594A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016512198A (ja
JP6318180B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/020700 external-priority patent/WO2014138212A1/en
Publication of JP2016512198A publication Critical patent/JP2016512198A/ja
Publication of JP2016512198A5 publication Critical patent/JP2016512198A5/ja
Application granted granted Critical
Publication of JP6318180B2 publication Critical patent/JP6318180B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015561594A 2013-03-06 2014-03-05 ＣａＭＫＩＩ阻害剤及びその使用 Expired - Fee Related JP6318180B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361773779P 2013-03-06 2013-03-06
US61/773,779 2013-03-06
PCT/US2014/020700 WO2014138212A1 (en) 2013-03-06 2014-03-05 CaMKII INHIBITORS AND USES THEREOF

Publications (3)

Publication Number Publication Date
JP2016512198A JP2016512198A (ja) 2016-04-25
JP2016512198A5 true JP2016512198A5 (enExample) 2017-04-06
JP6318180B2 JP6318180B2 (ja) 2018-04-25

Family

ID=51491905

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015561594A Expired - Fee Related JP6318180B2 (ja) 2013-03-06 2014-03-05 ＣａＭＫＩＩ阻害剤及びその使用

Country Status (7)

Country Link
US (1) US9951061B2 (enExample)
EP (1) EP2964225B1 (enExample)
JP (1) JP6318180B2 (enExample)
CN (1) CN105517549B (enExample)
AU (1) AU2014225889B2 (enExample)
CA (1) CA2901155C (enExample)
WO (1) WO2014138212A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015311730A1 (en) 2014-09-05 2017-04-20 Allosteros Therapeutics, Inc Camkii inhibitors and uses thereof
JP6532737B2 (ja) * 2015-04-01 2019-06-19 東ソー・ファインケム株式会社 ヘテロアセン化合物の製造方法
AR110252A1 (es) * 2016-11-30 2019-03-13 Gilead Sciences Inc Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam
MX2020000090A (es) * 2017-07-06 2020-08-06 Childrens Medical Center Composiciones y metodos para tratar o prevenir la taquicardia ventricular polimorfica catecolaminergica.
CA3091789A1 (en) 2018-02-21 2019-08-29 Bristol-Myers Squibb Company Camk2d antisense oligonucleotides and uses thereof
CN108904532B (zh) * 2018-08-20 2021-07-27 上海市第一人民医院 一种富勒烯C60纳米晶体联合CaMKII抑制剂的组合物的应用
US20240100042A1 (en) * 2020-11-20 2024-03-28 Sailing Pharmaceutical Technology Group Co., Ltd Brucine gel plaster and preparation method and use thereof
WO2024197267A1 (en) * 2023-03-22 2024-09-26 The Regents Of The University Of Colorado, A Body Corporate Inhibitors of ca 2+/calmodulin-dependent protein kinase ii (camkii) that do not inhibit long-term potentiation (ltp) induction and therapeutic uses thereof
WO2025101615A1 (en) * 2023-11-07 2025-05-15 Cardurion Pharmaceuticals, Inc. Polymorphs of a pyridinylimidazo[1,2-b]pyridazine

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2178157T3 (es) 1997-01-31 2002-12-16 Univ Leland Stanford Junior Tratamiento de arritmias mediante la inhibicion de una proteina quinasa multifuncional dependiente de calcio/calmodulina.
EP1439849A4 (en) 2001-10-01 2005-09-28 Univ Vanderbilt USE OF CALMODULIN KINASE II INHIBITORS FOR THE TREATMENT OF MYOCARDIAL FUNCTIONAL DISORDERS IN STRUCTURAL HEART DISEASE
WO2004058764A1 (en) * 2002-12-27 2004-07-15 Bayer Healthcare Ag 4-phenyl-pyrimido [4,5-b] indole derivatives
US20060057639A1 (en) 2004-06-16 2006-03-16 Pitt Geoffrey S CaMKII/calcium channel phosphorylation-related compositions and methods
WO2006049215A1 (ja) 2004-11-02 2006-05-11 Dainippon Sumitomo Pharma Co., Ltd. 自己免疫疾患を治療するための併用薬
BRPI0610828A2 (pt) * 2005-05-16 2010-07-27 Irm Llc compostos e composições como inibidores de proteìna quinase
KR20080016659A (ko) * 2005-05-20 2008-02-21 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제의 억제제로서 유용한 피롤로피리딘
EP1896472A1 (de) * 2005-06-09 2008-03-12 Boehringer Ingelheim International GmbH Alpha-carboline als cdk-1 inhibitoren
JP2009523812A (ja) * 2006-01-19 2009-06-25 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド 融合へテロ二環式キナーゼ阻害剤
CL2008001540A1 (es) * 2007-05-29 2009-05-22 Sgx Pharmaceuticals Inc Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer.
EP2161271A1 (en) * 2008-09-08 2010-03-10 Università Degli Studi Di Milano - Bicocca Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl
US8440656B2 (en) 2009-06-22 2013-05-14 University Of Iowa Research Foundation Methods of treating pulmonary diseases and disorders by modulating calcium/calmodulin dependent protein kinase II activity
US8685969B2 (en) * 2010-06-16 2014-04-01 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors

Similar Documents

Publication Publication Date Title
PH12018550049A1 (en) Protein kinase inhibitor, preparation method and medical use thereof
JP2013010792A5 (enExample)
JP2017534572A5 (enExample)
JP2016538257A5 (enExample)
HU226138B1 (en) R-enantiomer of n-propargyl-1-aminoindan, salts, compositions and uses thereof
JP2019524897A5 (enExample)
JP2010511701A5 (enExample)
JP2013540114A5 (enExample)
CY1109370T1 (el) Παραγωγα οξαδιαζολονης ως ppar δελτα αγωνιστες
JP2017524733A5 (enExample)
CN102497864A (zh) 用于预防或治疗由化疗诱发的疼痛的σ配体
SA109300394B1 (ar) ثيازوليل- وأوكسازوليل- أيزوكوينولينونات وطرق لاستخدامها
JP2011518168A5 (enExample)
JP2022523702A (ja) トランス－４－ヒドロキシシクロヘキシルフェニルアミドマイトフュージン活性化物質及びその使用方法
JP2014532751A5 (enExample)
CO6341628A2 (es) \\\\\\\"nuevos compuestos adecuados como precursores de compuestos que son utiles para obtener imegenes de depositos amiloides\\\\\\\"
KR20120099212A (ko) 트라마돌 및 콕시브의 공결정
ES2924728T3 (es) Derivados de carbazol para el tratamiento de enfermedades fibróticas, así como de síntomas y afecciones relacionados con las mismas
US9914741B2 (en) Tetrahydroisoquinoline derivatives
CN106458878B (zh) 2-氰基-3-环丙基-3-羟基-n-芳基-硫代丙烯酰胺衍生物
JP2015515496A5 (enExample)
RU2013107659A (ru) ИНГИБИТОР КАЗЕИНКИНАЗЫ 1δ И КАЗЕИНКИНАЗЫ 1ε
JP5960695B2 (ja) パンテニルドコサヘキサエノアート、ならびに心血管疾患を治療および予防するためのその使用
JP4964593B2 (ja) 神経学的病状の治療用のテトラヒドロインドロン誘導体
CN104177324B (zh) 呫吨酮类化合物及其抗抑郁用途